Why the study?
Does an array-based resequencing assay accurately detect mutations in HCM-associated genes compared to conventional capillary sequencing?
Population
24 reference samples for hypertrophic cardiomyopathy (HCM) genetic testing
Comparison
Array-based resequencing assay covering MYH7… vs Conventional capillary sequencing
Design
Other
Key result
An array-based resequencing assay detected the underlying point mutation in 23 of 24 reference samples, demonstrating ≥99.9% comparability to conventional capillary sequencing.
Authors
Loading...
Warrants no change in HCM genetic testing protocols; leaves open utility of array-based resequencing pending larger validation.
Does an array-based resequencing assay accurately detect mutations in HCM-associated genes compared to conventional capillary sequencing?
Effect estimate: ≥99.9% comparability
An array-based resequencing assay provides a highly accurate and potentially more efficient alternative to conventional capillary sequencing for genetic testing in hypertrophic cardiomyopathy.
Waldmüller et al. (2008) studied Hypertrophic cardiomyopathy (n=24). Array-based resequencing (ABR) assay vs. Conventional capillary sequencing was evaluated on Detection of underlying point mutations and comparability to conventional capillary sequencing (≥99.9% comparability). An array-based resequencing assay detected the underlying point mutation in 23 of 24 reference samples, demonstrating ≥99.9% comparability to conventional capillary sequencing.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: